StockData
INSMED Inc logo

INSMED Inc (INSM) stock

INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3099% above fair value
$119.80−2.06 (-1.69%)

Close on Nov 18, 2026Market cap $26.28BP/E –Yield –

Insmed operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Insmed's operating income for the twelve months ending Sep 30, 2026 was -$563.99M. For fiscal 2025 it was -$1.25B. The highest annual figure on record is -$8.09M in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.25B–
FY2024Dec 31, 2024-$878.25M–
FY2023Dec 31, 2023-$709.63M–
FY2022Dec 31, 2022-$457.32M–
FY2021Dec 31, 2021-$375.09M–
FY2020Dec 31, 2020-$265.23M–
FY2019Dec 31, 2019-$235.25M–
FY2018Dec 31, 2018-$307.34M–
FY2017Dec 31, 2017-$188.92M–
FY2016Dec 31, 2016-$173.40M–
FY2015Dec 31, 2015-$117.49M–
FY2014Dec 31, 2014-$87.37M–
FY2013Dec 31, 2013-$55.02M–
FY2012Dec 31, 2012-$42.44M–
FY2011Dec 31, 2011-$61.72M–
FY2010Dec 31, 2010-$8.09M–
FY2009Dec 31, 2009-$8.67M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$89.37M–
Q2 FY2026Jun 30, 2026-$1.55M–
Q1 FY2026Mar 31, 2026-$153.32M–
Q4 FY2025Dec 31, 2025-$319.75M–
Q3 FY2025Sep 30, 2025-$366.01M–
Q2 FY2025Jun 30, 2025-$312.88M–
Q1 FY2025Mar 31, 2025-$248.14M–
Q4 FY2024Dec 31, 2024-$230.41M–
Q3 FY2024Sep 30, 2024-$213.43M–
Q2 FY2024Jun 30, 2024-$288.90M–
Q1 FY2024Mar 31, 2024-$145.51M–
Q4 FY2023Dec 31, 2023-$178.27M–
Q3 FY2023Sep 30, 2023-$147.67M–
Q2 FY2023Jun 30, 2023-$235.53M–
Q1 FY2023Mar 31, 2023-$148.16M–
Q4 FY2022Dec 31, 2022-$151.48M–
Q3 FY2022Sep 30, 2022-$127.70M–
Q2 FY2022Jun 30, 2022-$88.32M–
Q1 FY2022Mar 31, 2022-$89.83M–
Q4 FY2021Dec 31, 2021-$99.08M–
Q3 FY2021Sep 30, 2021-$103.62M–
Q2 FY2021Jun 30, 2021-$88.57M–
Q1 FY2021Mar 31, 2021-$83.83M–
Q4 FY2020Dec 31, 2020-$94.54M–
Q3 FY2020Sep 30, 2020-$56.22M–
Q2 FY2020Jun 30, 2020-$54.11M–
Q1 FY2020Mar 31, 2020-$60.36M–
Q4 FY2019Dec 31, 2019-$47.08M–
Q3 FY2019Sep 30, 2019-$56.49M–
Q2 FY2019Jun 30, 2019-$62.17M–
Q1 FY2019Mar 31, 2019-$69.51M–
Q4 FY2018Dec 31, 2018-$87.72M–
Q3 FY2018Sep 30, 2018-$83.98M–
Q2 FY2018Jun 30, 2018-$72.88M–
Q1 FY2018Mar 31, 2018-$62.75M–
Q4 FY2017Dec 31, 2017-$65.35M–
Q3 FY2017Sep 30, 2017-$44.08M–
Q2 FY2017Jun 30, 2017-$43.52M–
Q1 FY2017Mar 31, 2017-$35.97M–
Q4 FY2016Dec 31, 2016-$67.05M–

More Insmed figures

See a number that looks wrong?